Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials
Quick Take
GLP-1 receptor agonists (GLP-1 RAs) consistently reduce Major Adverse Cardiovascular Events (MACE). This benefit is now firmly established in Type 2 Diabetes (T2D) and is rapidly expanding into non-diabetic populations with obesity and established cardiovascular disease.
💡 Clinical Impact
* The "Mechanistic Why": GLP-1 RAs offer pleiotropic benefits